News

Accelerated approval was granted by the FDA to ponatinib plus chemo for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

A next-generation stool DNA test had higher sensitivity for CRC and advanced precancerous lesions but lower specificity for advanced neoplasia compared with a fecal immunochemical test.

An expert explained the importance of having strong communication skills not only for all patients with cancer, but especially for those who received a terminal diagnosis.

The Oncologic Drugs Advisory Committee of the FDA unanimously voted in favor of ciltacabtagene autoleucel for the treatment of early relapsed/refractory myeloma.

Compared with placebo, first-line niraparib maintenance was not linked with worsened health-related quality of life outcomes in patients with advanced ovarian cancer.

The FDA granted an orphan drug designation to avutometinib either alone or in combination with defactinib for recurrent low-grade serous ovarian cancer.

The benefits of imetelstat outweigh the risks for anemia treatment in lower-risk myelodysplastic syndrome, according to a vote by the FDA’s Oncologic Drugs Advisory Committee.

Accelerated approval has been granted by the FDA to lisocabtagene maraleucel for the treatment of certain patients with relapsed/refractory CLL or SLL.

Tislelizumab-jsgr (Tevimbra) has been approved for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) among adult patients who have previously received systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

The use of nivolumab plus chemotherapy as a standard frontline treatment has been supported by recent data from the phase 3 CheckMate 649 trial for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Treatment for relapsed or refractory diffuse large B-cell lymphoma with brentuximab vedotin, lenalidomide, and rituximab contributed to an improvement in overall survival vs lenalidomide/rituximab/placebo.

With the progress made with ADCs, there is interest in moving these agents up in the treatment paradigm for HR-positive/HER2-negative breast cancer.

Simple hysterectomy was shown to reduce the incidence of urinary incontinence vs radical hysterectomy for low-risk cervical cancer.

Based on results from a post hoc analysis, researchers found that lurbinectedin was more effective and less toxic than topotecan for the treatment of small cell lung cancer.

In a 16-to-2 vote, the FDA's Medical Imaging Drugs Advisory Committee voted in support of the benefit-risk profile of Lumisight to detect cancerous tissue during breast conservation surgery.

Cancer teams, including oncology nurses, can make conscious choices to potentially alleviate the disparities that persist in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Disease-free survival rates were extended in patients with upper tract urothelial cancer treated with adjuvant chemotherapy after nephroureterectomy compared with those who underwent surveillance.

A biologics license application has been accepted by the FDA for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer.

Many symptoms related to endometrial cancer may improve within 1 year in women with endometrial cancer, with the exception of those with high-risk disease.

Patients with unresectable or metastatic melanoma treated with the universal cancer vaccine UV1 plus nivolumab and ipilimumab did not experience an improvement in progression-free survival vs nivolumab plus ipilimumab alone.

The FDA approved zanubrutinib plus obinutuzumab for the treatment of patients with relapsed or refractory follicular lymphoma after receiving 2 or more lines of systemic therapy.

Nivolumab plus cisplatin and gemcitabine received FDA approval for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

Patients with phlebotomy-dependent polycythemia vera, a type of myeloproliferative neoplasm, treated with rusfertide experienced greater responses compared with those treated with placebo.

The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.

Although frontline treatment with lenvatinib plus pembrolizumab improved ORR and PFS, it did not improve OS when compared with placebo in patients with head and neck squamous cell carcinoma.

Patients with FIGO stage IV ovarian cancer did not experience additional complications or worse survival with HIPEC compared with those with stage III disease.